Ask who will evaluate you, how to verify credentials, what exact product and use are proposed, which pharmacy is involved, what evidence and risks apply, how follow-up works, and what the total cost includes.
1. Can the practitioner explain, in plain terms, why a peptide is being compounded under section 503A — and which pharmacy they work with?
A credible clinician will articulate the regulatory rationale without marketing language. They should name the 503A pharmacy and be willing to discuss its inspection history. If a clinic deflects this question, that deflection is the answer.
2. Will baseline labs — IGF-1, hormone panels, metabolic markers — be drawn before any protocol begins?
A practitioner operating to a defensible standard will not write a sermorelin or CJC-1295 prescription without an IGF-1 baseline. If an Oklahoma City clinic is willing to ship product without a workup, the real question is not whether the price is fair. Documentation that holds up is not optional.
3. What is the follow-up cadence — three months, six months — and who reviews the labs?
Anti-aging protocols are not one-and-done prescriptions. The physician or a credentialed nurse practitioner under direct physician oversight should review repeat labs at fixed checkpoints and adjust dose, frequency, or cessation based on the values. Ask who reviews the labs and how that review is documented.
4. What conditions would cause the physician to stop the protocol — and how is that decision made?
A practitioner who cannot describe their stop-criteria has not thought through the risk. Reasonable answers include out-of-range IGF-1, adverse event, lack of measurable improvement at a defined checkpoint, or any new contraindication identified during follow-up. If the answer is "we just keep going," the patient will eventually be asked to defend that decision, not the clinic.